As we age, a growing population of “senescent” cells stops dividing but refuses to die, and instead pumps out a toxic cocktail of inflammatory signals that damages surrounding tissue. This review organizes the entire anti-senescence drug field into three strategies: kill the bad cells (senolytics), recruit the immune system to hunt them (immuno-senolytics), or silence their toxic secretions without killing them (senomorphics). The authors argue the field is shifting from crude, broad chemical clearance toward precise, personalized targeting, but caution that no strategy has yet cleared the hurdles of cell heterogeneity, missing biomarkers, and off-target toxicity that stand between the lab and the clinic.
There is a particular kind of cell that scientists have taken to calling a zombie. It is old, it has stopped dividing, and by all rights it should have quietly died. Instead it lingers in your tissues, metabolically hyperactive, spraying its neighbors with inflammatory molecules, matrix-chewing enzymes, and growth factors. Biologists call this spray the senescence-associated secretory phenotype, or SASP, and they increasingly believe its slow drip is a central engine of aging itself, feeding atherosclerosis, Alzheimer’s, pulmonary fibrosis, osteoarthritis, and diabetic kidney disease.
This review, from a team at Southwest Minzu University and the Sichuan Academy of Medical Sciences, steps back from the individual battles and maps the whole campaign. The authors sort the anti-aging arsenal into three tactical doctrines they nickname cleaning, chasing, and calming.
Cleaning is the senolytics approach: drugs that exploit the survival tricks these zombie cells rely on and push them into the programmed death they have been avoiding. This is the most mature branch, spanning repurposed cancer drugs like the BCL-2 blockers, the widely discussed dasatinib-plus-quercetin combination, and a long roster of plant compounds such as fisetin, luteolin, and salidroside.
Chasing is the newest and arguably most exciting doctrine: immuno-senolytics. Rather than dosing the body with a drug, these approaches weaponize the immune system. They include vaccines that train the body to recognize a senescence marker called GPNMB, engineered CAR-NK and CAR-T cells built to hunt senescent targets, and antibodies that strip away the “don’t eat me” signals senescent cells use to hide from immune patrols. The promise here is durability: a single vaccination could, in principle, provide years of immune memory.
Calming is the most conservative doctrine: senomorphics. These drugs do not kill anything. They muzzle the SASP by blocking the signaling hubs (mTOR, NF-kB, p38 MAPK, JAK-STAT) that drive the toxic secretions, or by rewiring the epigenetic machinery upstream. Rapamycin, metformin, and even the gut bacterial metabolite butyrate fall into this camp.
The big idea is that these are not competitors but complements. The field’s frontier, the authors argue, is combination and sequence: clear the worst offenders, then calm the survivors, ideally with tissue-targeted delivery so you are not clearing senescent cells indiscriminately. That last caveat is the sting in the tail. Senescent cells are not purely villains. During wound healing they are essential, and wiping them out at the wrong moment can delay repair. The review’s honest conclusion is that anti-aging medicine is standing at a threshold, not across it. [Confidence: Medium]
Actionable Insights
Be careful here. This is a review, and its persuasive language often outruns its evidence. Almost every quantitative claim is inherited from a cited primary study, not measured here, and effect sizes are essentially absent from the text. With that caveat, the take-home messages are as follows.
The single most translated intervention mentioned is dasatinib plus quercetin. The paper cites the 2019 Hickson human pilot (diabetic kidney disease) showing senolytics can reduce senescent cell burden in people. In that original trial the senescent-cell marker p16 fell meaningfully in fat and skin over 11 days, but the sample was 9 patients with no placebo arm, so the real-world magnitude is not established by this review. [Confidence: Low, because the effect size is not reported here and the underlying trial is tiny]
Fisetin is flagged as the leading nutraceutical senolytic, with human trials ongoing. The review states its senolytic efficacy is “comparable to genetic ablation” in animals, but gives no numbers. Practically, fisetin is a widely available flavonoid, and the “hit-and-run” intermittent dosing model (short high-dose pulses rather than daily use) is the strategy under study.
The everyday compounds with the strongest safety record here are metformin, rapamycin, resveratrol, spermidine, and N-acetylcysteine, all classed as SASP-calmers rather than cell-killers. The one hard population-level signal cited is pioglitazone: long-term users showed reduced all-cause mortality. That is an association, not a causal effect size, and pioglitazone carries weight-gain and edema risk. [Confidence: Medium for the association, Low for causal benefit]
Bottom line for a self-experimenter: nothing in this paper establishes a quantified longevity benefit in humans. It maps promising targets, not proven protocols.
Context and Source
- Open access paper: Cleaning, Chasing and Calming: Promising Paradigms of Senotherapy in Aging-Related Diseases.
- Article type: Review.
- Institutions: Southwest Minzu University (College of Pharmacy and Food), Chengdu; and the Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, affiliated with the University of Electronic Science and Technology of China, Chengdu; with Dazhou First People’s Hospital.
- Country: China.
- Journal: International Journal of Biological Sciences (Ivyspring International Publisher), published July 20 2026.
- Impact evaluation: The impact score of this journal is 11.7 (2026 Journal Citation Reports impact factor; CiteScore is 12.9), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.